Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs

Business Wire July 31, 2014

Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies

Business Wire July 30, 2014

Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information

Business Wire July 28, 2014

Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia Vera

Business Wire July 23, 2014

Incyte to Report Second Quarter 2014 Financial Results on July 31

Business Wire July 14, 2014

Incyte Achieves $25 Million Milestone for Approval of Jakavi® (ruxolitinib) in Japan

Business Wire July 8, 2014

Immuno-Oncology Game-Changers from Big Pharma and Small Biotechs

Equities.com June 30, 2014

Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before

Accesswire June 26, 2014

Incyte to Present at the 9th Annual JMP Securities Healthcare Conference

Business Wire June 12, 2014

Geron (GERN) Gains After FDA Green Lights Imetelstat Trial Resumption

Equities.com June 12, 2014

Looking at the Latest in Immunotherapies

Equities.com June 5, 2014

Pivotal Phase III Data in Polycythemia Vera Show that Jakafi® (ruxolitinib) Achieved Superior Disease Control Compared to Best Available Therapies

Business Wire June 3, 2014

Incyte Announces Full Results from Proof-of-Concept Phase II RECAP Trial of Jakafi® (ruxolitinib) in Combination with Capecitabine in Patients with Metastatic Pancreatic Cancer

Business Wire June 2, 2014

Incyte Announces Preliminary Results of a Phase I/II Study of Combination Immunotherapy in Patients with Melanoma

Business Wire June 2, 2014

New Data for Multiple Incyte Cancer Programs to Be Presented at the 2014 American Society of Clinical Oncology (ASCO) Meeting

Business Wire May 28, 2014

Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies

Business Wire May 27, 2014

Incyte to Present at Upcoming Investor Conferences

Business Wire May 20, 2014

Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets

Accesswire May 14, 2014

Incyte and MedImmune Announce Collaboration on Immuno-Oncology Combination Clinical Trial

Business Wire May 14, 2014

Incyte to Present at Upcoming Investor Conferences

Business Wire May 2, 2014